Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor, Hannah Chory, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Alberto Guijosa, Nickolas Tsakmaklis, Zachary Hunter, Andrew Branagan, Steven Treon, Jorge Castillo

Blood (2025) 146 (Supplement 1): 581.

https://doi.org/10.1182/blood-2025-581

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

Jorge Castillo, Andrew Branagan, Gottfried von Keudell, Alberto Guijosa, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, Zachary Hunter, Steven Treon, Shayna Sarosiek

Blood (2025) 146 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2025-1794

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Andres Ramirez-Gamero, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2024-198376

Published: 2024

Journal Articles

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Gottfried von Keudell, Catherine A. Flynn, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Andres Ramirez-Gamero, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Christopher J Patterson, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2024-198297

Published: 2024

Journal Articles

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Blood (2024) 144 (Supplement 1): 2972.

https://doi.org/10.1182/blood-2024-211759

Published: 2024

Journal Articles

Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom's Macroglobulinemia (WM)

Zachary R Hunter, Andres Felipe Ramirez Gamero, Maria Luisa Guerrera, Nickolas Tsakmaklis, Amanda Kofides, Xia Liu, Shirong Liu, Abigail Peachey, Hao Sun, Catherine A. Flynn, Kirsten Meid, Joshua Gutine, Christopher J Patterson, Shayna R Sarosiek, Jorge J. Castillo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 2968.

https://doi.org/10.1182/blood-2024-211664

Published: 2024

Journal Articles

A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia

Jorge J. Castillo, Steven P. Treon, Catherine A. Flynn, Andres Ramirez-Gamero, Nina S Budano, Alexandra N. Eurell, Kirsten Meid, Shayna R Sarosiek

Blood (2024) 144 (Supplement 1): 4404.

https://doi.org/10.1182/blood-2024-211573

Published: 2024

Journal Articles

Pacritinib Effectively Inhibits Pro-Survival Signaling and Overcomes BTK Cys481Ser -Mediated Resistance in MYD88-Mutated B-Cell Malignancies

Shirong Liu, Amanda Kofides, Xia Liu, Hao Sun, Alexa G Canning, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Kirsten Meid, Prafulla C. Gokhale, John M Hatcher, Jorge J. Castillo, Shayna R Sarosiek, Steven P. Treon

Blood (2024) 144 (Supplement 1): 5830.

https://doi.org/10.1182/blood-2024-211285

Published: 2024

Journal Articles

Analysis of Alternative Splicing in Waldenstrom's Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates

Zachary R Hunter, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Abigail Peachey, Andres Felipe Ramirez Gamero, John M Hatcher, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C. Munshi, Shayna R Sarosiek, Jorge J. Castillo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 2986.

https://doi.org/10.1182/blood-2024-212123

Published: 2024

Journal Articles

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Jorge J. Castillo, Andrew R. Branagan, David Sermer, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy White, Alexa Canning, Maria L. Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, Christopher J. Patterson, Zachary R. Hunter, Steven P. Treon, Shayna Sarosiek

Blood (2024) 143 (7): 582–591.

https://doi.org/10.1182/blood.2023022420

Published: 2024

Includes: Supplemental data

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Blood (2023) 142 (Supplement 1): 756.

https://doi.org/10.1182/blood-2023-190685

Published: 2023

Journal Articles

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Shirong Liu, Amanda Kofides, Xia Liu, Alexa G Canning, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Zachary R Hunter, Kris Richardson, Catherine A. Flynn, Kirsten Meid, Megan Little, Katherine Stockman, Timothy P. White, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 3300.

https://doi.org/10.1182/blood-2023-190463

Published: 2023

Journal Articles

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, Shayna R Sarosiek, Andrew R. Branagan, Catherine A. Flynn, Megan Little, Katherine Stockman, Timothy P. White, Alexandra N. Eurell, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nickolas Tsakmaklis, Kirsten Meid, Christopher J Patterson, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2023-174375

Published: 2023

Journal Articles

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Nickolas Tsakmaklis, Zachary R Hunter, Xia Liu, Amanda Kofides, Shirong Liu, Alexa G Canning, Kris Richardson, Maria Luisa Guerrera, Christopher J Patterson, Kirsten Meid, Timothy P. White, Megan Little, Katherine Stockman, Joshua Gustine, Catherine A. Flynn, Andrew R. Branagan, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon

Blood (2023) 142 (Supplement 1): 211.

https://doi.org/10.1182/blood-2023-190520

Published: 2023

Journal Articles

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Nickolas Tsakmaklis, Kris Richardson, Shirong Liu, Christopher J Patterson, Catherine A. Flynn, Kirsten Meid, Nikhil C Munshi, Kenneth C. Anderson, Shayna R Sarosiek, Jorge J. Castillo, Steven P Treon, Zachary R Hunter

Blood (2023) 142 (Supplement 1): 1952.

https://doi.org/10.1182/blood-2023-190942

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis

Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström's Macroglobulinemia and Represent Novel Therapeutic Targets.

Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom's Macroglobulinemia (WM)

A Phase II Trial of Loncastuximab Tesirine in Patients with Previously Treated Waldenström Macroglobulinemia

Pacritinib Effectively Inhibits Pro-Survival Signaling and Overcomes BTK Cys481Ser -Mediated Resistance in MYD88-Mutated B-Cell Malignancies

Analysis of Alternative Splicing in Waldenstrom's Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Pacritinib Blocks Key Pro-Survival Signaling Related to Mutated MYD88, Produces High Levels of Apoptosis and Overcomes Mutated BTK Cys481 Related BTK-Inhibitor Resistance

Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia

Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia

Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only